Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Pancreatic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Melanoma 1 Glioblastoma 1 Brain Neoplasms 1

Interventions

pembrolizumab 74 Nivolumab 53 Ipilimumab 42 Cyclophosphamide 32 Interleukin-2 24 aldesleukin 23 Temozolomide 17 fludarabine 16 Biopsy 11 trametinib 10 fludarabine phosphate 10 dabrafenib 10 spartalizumab 8 Paclitaxel 8 Dacarbazine 8 sargramostim 7 cemiplimab 7 binimetinib 7 Cisplatin 7 Bevacizumab 7 poly ICLC 6 lenvatinib 6 epacadostat 6 Radiotherapy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5 encorafenib 5 atezolizumab 5 Vemurafenib 5 Specimen Handling 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × defactinib × Clear all

NCT06194929 2025-12-03

DETERMINE

University of Utah

Phase 1/2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡